PsA ACR RESPONDER RATES
Durable improvements in joint pain and stiffness through 4 years, NRI1,5,32
Study: RAPID-PsA1,10a
Primary Endpoint
RAPID-PsA ACR20 responder rates through 4 years1,10,32b
The same patients may not have responded at each time point
Placebo rates at Week 241,10
The ACR response criteria assess changes in swollen and tender joints, pain, functional ability, patient and physician assessment, and acute phase reactant33
Limitation of OLE: ACR Responder Rates do not have long-term placebo comparator beyond Week 2432
- RS-NRI: randomized set nonresponder imputation.
- Line graph to Week 216 represents patients who were randomized initially to CIMZIA 200 mg Q2W.
ACR, American College of Rheumatology; NRI, nonresponder imputation; PsA, psoriatic arthritis; Q2W, every 2 weeks.
CIMZIA inhibited radiographic progression compared to placebo at Week 241a
8 out of 10 x-rayed patients receiving CIMZIA 200 mg Q2W experienced no radiographic progression over 4 years (n=98)32b
Patients treated with CIMZIA 400 mg Q4W did not demonstrate greater inhibition of radiographic progression compared with placebo-treated patients at Week 241
- For placebo patients who escaped early to CIMZIA, the Week 24 values were linearly extrapolated. The P value of CIMZIA vs placebo is based on analysis of covariance. For patients with 2 radiographs but a missing Week 24 or baseline film, linear extrapolation was performed in all approaches.
- Limitation of 4 year data: Open label extension does not have a placebo control arm. ‘No progression’ was defined as a change from baseline in mTSS of ≤0.5. When ‘no progression’ was defined as a change from baseline in mTSS of ≤0, 63.3% of x-rayed patients experienced no progression.
mTSS, modified Total Sharp Score; Q2W, every 2 weeks; Q4W, every 4 weeks.
